Hi, we've made some changes

ValiRx(VAL)

Sector:

Pharmaceuticals & Biotechnology

Index:

FTSE AIM All-Share

Market Cap

£2.79m

Change Today

Price Down-0.25p

Share Price

6.00p

ValiRx granted Aussie patent for GeneICE

Date: Tuesday 29 Jan 2008

LONDON (ShareCast) - ValiRx headed higher Tuesday after the cancer treatment company said its proprietary gene-silencing technology, GeneICE, has received patent approval in Australia.

The AIM firm, which was granted a US patent in April last year and a European patent in August 2007, holds the rights to GeneICE through its subsidiary, Cronos Therapeutics.

Cronos has an exclusive worldwide license agreement with Imperial College Innovations.

Its partner, Cancer Research UK, has recently completed phase one of its pre-clinical trials on GeneICE, which has the potential to freeze the development and growth of cancerous cells.

The trials showed GeneICE triggered cell death in ovarian, pancreatic and prostate cancer cells and could potentially be relevant to other cancers.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

ValiRx Market Data

Currency UK Pounds
Share Price 6.00p Price Down
Change Today -0.25p
52 Week High 23.25p
52 Week Low 6.00p
Volume 23,000
Shares Issued 46.50m
Market Cap £2.79m
Beta 0.30
RiskGrade 227

Performance Indicators

Compare performance with the sector and the market.
Find out more
Key: vs Market vs Sector
Value
12.54% below the market average12.54% below the market average12.54% below the market average12.54% below the market average12.54% below the market average
8.43% above the sector average8.43% above the sector average8.43% above the sector average8.43% above the sector average8.43% above the sector average
Price Trend
67.13% below the market average67.13% below the market average67.13% below the market average67.13% below the market average67.13% below the market average
47.25% below the sector average47.25% below the sector average47.25% below the sector average47.25% below the sector average47.25% below the sector average
Income Not Available
Growth
29.24% below the market average29.24% below the market average29.24% below the market average29.24% below the market average29.24% below the market average
44% below the sector average44% below the sector average44% below the sector average44% below the sector average44% below the sector average
Price Chg 6m
66.75% below the market average66.75% below the market average66.75% below the market average66.75% below the market average66.75% below the market average
60.44% below the sector average60.44% below the sector average60.44% below the sector average60.44% below the sector average60.44% below the sector average
P/E Not Available
PEG Not Available
Dividend Yield Not Available
EPS Growth Not Available
Operating Margin
95.27% below the market average95.27% below the market average95.27% below the market average95.27% below the market average95.27% below the market average
50.65% below the sector average50.65% below the sector average50.65% below the sector average50.65% below the sector average50.65% below the sector average

ValiRx Dividends

No dividends found

Trades for 09-Jul-2008

Time Volume / Share Price
10:57 20,000 @ 6.15p
10:25 3,000 @ 6.00p

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).